Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has ...

In biopharmaceutical development, clinical trials generate vast amounts of data from various experimental sources and methods ...

Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...

Johnson Johnson (NYSE: JNJ) announced plans to invest over $55 billion in the United States over the next four years, ...

R. World Institutional Ranking (R. W I Ranking) proudly announces the release of the much-anticipated Green Rankings 2025, ...

SaveHealth reports on the third-party companies that work to negotiate discounts with pharmacies and pharmacy benefit ...

British investment firm SV Health Investors has secured $250 million to go toward the development of first-in-class ...

Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025 ...

Novo Nordisk is reorganizing its research and early development unit in an effort to “future-proof the organization” and ...

Qube Integrated Malaysia Sdn. Bhd., the organiser of SEACare 2025, is proud to announce the inaugural SEA Healthcare and Pharma Conference ...